Education
About Us
Working with TipRanks
Follow Us
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
CNTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.86
Previous CloseN/A
Volume1.98K
Average Volume (3M)214.07K
Market Cap
$110.70M
Enterprise Value-$17.37M
Total Cash (Recent Filing)$93.71M
Total Debt (Recent Filing)$178.00K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 16, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,561,054
10 Day Avg. Volume300,354
30 Day Avg. Volume214,066
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-0.67
Enterprise Value/Gross Profit-0.68
Enterprise Value/Ebitda1.18
Forecast
1Y Price Target
$7.25Price Target Upside255.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityConnect Biopharma Holdings is eligible to receive milestone payments up to approximately $110M and royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China, which could provide financial flexibility to invest further in development without diluting shareholders.
Market OpportunityThe large market opportunity in COPD and asthma, along with rademikibart's unique mechanism of action, suggests it could become the therapy of choice in both acute and chronic settings.
Regulatory ProgressCNTB announced positive feedback from its Type C meeting with the FDA and is on track to initiate parallel Phase 2 proof-of-concept trials for lead asset rademikibart.
Bears Say
Clinical RisksRisks include safety signals emerge with any of the company’s clinical or preclinical programs, efficacy from clinical programs is lower than expected, or the company’s studies do not achieve statistical significance.
CompetitionConnect Biopharma is planning a Phase 2 trial for rademikibart to treat acute exacerbations due to asthma or COPD, which is a market with no existing competition from approved drugs like Dupixent.
Financing RequirementsFinancing requirements for the business assume cash runway into 2027 and approximately $150M additional financing needed through 2038.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.51 and its highest was $2.86 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $110.70M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Sep 16, 2025 which is in 41 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Currently, no data Available
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.22.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 55,561,054 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
Connect Biopharma Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.25 (255.39% Upside)
$7.25 (255.39% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.49%
12-Months-Change
Fundamentals
Return on Equity
-58.89%
Trailing 12-Months
Asset Growth
-15.87%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$7.25
▲(255.39%Upside)
Technical Analysis
Dyadic International
―
X4 Pharmaceuticals
―
Reviva Pharmaceuticals Holdings
―
PepGen Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
11.70%
Insiders
0.05% Mutual Funds
4.70% Other Institutional Investors
95.25% Public Companies and
Individual Investors